Julphar Announces Strategic Licensing Partnership with Dong A ST to Launch Innovative Biotechnology Product in MENA

05^th March 2025, Ras Al Khaimah, UAE: Gulf Pharmaceutical Industries (Julphar), a prominent leading pharmaceutical company in the MENA region, today announced a new exclusive licensing partnership with Dong-A ST, one of South Korea’s most reputable pharmaceutical companies.

Under this agreement, Julphar will exclusively tech transfer, manufacture and commercialize Darbepoetin Alfa biosimilar, a long-acting Erythropoietin formulation developed by Dong-A ST, in the MENA region.

This strategic collaboration is a further step in Julphar’s strategy to expand its biologics portfolio and underscores the company’s commitment to enhancing access to innovative, high-quality healthcare solutions throughout the MENA region.

Basel Ziyadeh, Chief Executive Officer of Julphar: “This partnership aligns with Julphar's strategic vision to offer best-in-class products that meet the evolving needs of patients across the MENA region. Through this collaboration, Julphar and Dong-A ST aim to set new standards for biotechnology-based therapies, ensuring wider availability of life-changing treatments to improve therapy outcomes.”

Jung Jae-Hun, President of Dong A ST: “Dong-A ST will work closely with Julphar to ensure that Darbepoetin Alfa biosimilar is promptly utilized for the treatment of patients with CKD in MENA region. Furthermore, leveraging this collaboration, we will strive to expand access to Darbepoetin Alfa biosimilar for patients not only in MENA region but also worldwide, fulfilling our mission to enhance global health and well-being..”

-Ends-

About Julphar:

Julphar is a fast-growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of generic and in‐licensed products in the MENA region.

Julphar enhances healthcare access for millions across 16+ countries every day. For 45 years, Julphar has been dedicated to our customers offering a diverse portfolio of generic medicines. With a team of 3,400 passionate professionals, the company continues to shape a healthier world and improves community well-being. Julphar was established under the guidance of Sheikh Saqer Bin Mohammed Al Qasimi in 1980 and is headquartered in RAS Al-Khaimah, United Arab Emirates.

About Dong-A ST:

Dong-A ST is a globally renown ethical drug manufacturer, headquartered in South Korea. The company originated from the former Dong-A pharmaceutical company which was founded in 1932. With a workforce exceeding 1,600, the company is recognized for its expertise in developing, manufacturing, and distributing cutting-edge therapies across various therapeutic areas. Dong-A ST’s strong focus on biotechnology underscores its reputation as a trusted partner for innovative healthcare solutions in global markets.